Drug Channels: 2013 Pharmacy Market Share for Specialty Drugs – and the Biggest Players #pharmaceuticals #industry

Posted On Nov 26 2017 by

#pharmaceutical companies market share # Our research shows a booming market: In 2013, retail, mail, and specialty pharmacies dispensed about $63 billion in specialty pharmaceuticals. Specialty drugs accounted for 22% of total pharmacy industry revenues. Three companies Express Scripts, CVS Caremark, and Walgreens accounted for 63% of revenues from pharmacy-dispensed specialty drugs. The next three largest players had a combined share of about 5%. Read on for our market share estimates for the top players, observations on the market’s structure, and details of my panel discussion with specialty pharmacy leaders at next week s sPCMA Business Forum . THE NOMINEES …


The top 10 most expensive drugs of 2013 #alnylam #pharma

Posted On Nov 26 2017 by

#pharmaceutical companies news # The top 10 most expensive drugs of 2013 The price of Gilead Sciences’ breakthrough drug Sovaldi has drawn all of the attention this year. By pricing it at $85,000 for a 12-week course, Gilead Sciences ($GILD) has been pilloried by politicians, payers and providers. But as EvaluatePharma points out, at that price Sovaldi barely makes it into the top 20 most expensive drugs. number 19 to be exact, just above Novartis’ ($NVS) Gleevec and just below GlaxoSmithKline’s ($GSK) Mekinist. Sovaldi is pricey, but if you want to talk about really pricey, then look at the 10 …


Top 10 animal health companies of 2013 #pharma #job #search

Posted On Nov 10 2017 by

#leading pharmaceutical companies 2013 # Top 10 animal health companies of 2013 It is fascinating what has happened in the last couple of years in the animal health industry, which runs to $22 billion a year for animal drugs and vaccines and is expected to grow at 5.7% compound annual rate, faster than the market for human medicines. Zoetis ($ZTS) was spun off from Pfizer ($PFE) as the largest independent animal health company. M A action in recent months is remixing the players once again. Next year, Novartis ($NVS) will be off of this list, and based on current revenues, …


Drug Channels: 2013 Pharmacy Market Share for Specialty Drugs – and the Biggest Players #real #pharma

Posted On Nov 9 2017 by

#pharmaceutical companies market share # Our research shows a booming market: In 2013, retail, mail, and specialty pharmacies dispensed about $63 billion in specialty pharmaceuticals. Specialty drugs accounted for 22% of total pharmacy industry revenues. Three companies Express Scripts, CVS Caremark, and Walgreens accounted for 63% of revenues from pharmacy-dispensed specialty drugs. The next three largest players had a combined share of about 5%. Read on for our market share estimates for the top players, observations on the market’s structure, and details of my panel discussion with specialty pharmacy leaders at next week s sPCMA Business Forum . THE NOMINEES …


The top 10 most expensive drugs of 2013 #natco #pharma

Posted On Nov 8 2017 by

#pharmaceutical companies news # The top 10 most expensive drugs of 2013 The price of Gilead Sciences’ breakthrough drug Sovaldi has drawn all of the attention this year. By pricing it at $85,000 for a 12-week course, Gilead Sciences ($GILD) has been pilloried by politicians, payers and providers. But as EvaluatePharma points out, at that price Sovaldi barely makes it into the top 20 most expensive drugs. number 19 to be exact, just above Novartis’ ($NVS) Gleevec and just below GlaxoSmithKline’s ($GSK) Mekinist. Sovaldi is pricey, but if you want to talk about really pricey, then look at the 10 …


The Top 50 Global Pharma Companies 2013 #biotechnology #jobs

Posted On Nov 6 2017 by

#european pharmaceutical companies # The Top 50 Global Pharma Companies 2013 The Pharmaceutical Executive magazine published its annual ranking of the Top 50 Pharma Companies Worldwide based on sales earlier this month. New York -based Pfizer(PFE ) was topped the list with a sales of over $47.4 billion in 2012. The Top 50 Global Pharma Companies are listed in the tables below: Click to enlarge Here are a few observations: Swiss drug giant Novartis(NVS ) came in at number two with sales of over $45.0 billion. Among the top 10, five are European pharma companies including Novartis, Sanofi (SNY ), …


Top 10 animal health companies of 2013 #sk #pharma

Posted On Sep 21 2017 by

#leading pharmaceutical companies 2013 # Top 10 animal health companies of 2013 It is fascinating what has happened in the last couple of years in the animal health industry, which runs to $22 billion a year for animal drugs and vaccines and is expected to grow at 5.7% compound annual rate, faster than the market for human medicines. Zoetis ($ZTS) was spun off from Pfizer ($PFE) as the largest independent animal health company. M A action in recent months is remixing the players once again. Next year, Novartis ($NVS) will be off of this list, and based on current revenues, …


2013 so far: the pharmaceutical products making headway in the UK #aspenbio #pharma

Posted On Sep 10 2017 by

#pharmaceutical products # The pharmaceutical products set to make headway in the UK market, 2013 In the last few decades it s been widely reported that the UK s contribution to new pharmaceutical products has steadily declined overall, but last year broke the trend with a record-breaking 39 projects approved. The biggest slump in relatively recent times was in 1985 when only 11 new products went to market, and activity peaked in 1997 and again in 2010 with 34 product launches respectively. A detailed description of activity can be found here. This year, a new wave of medicines to treat …


The top 10 most expensive drugs of 2013 #basf #pharma

Posted On Sep 9 2017 by

#pharmaceutical companies news # The top 10 most expensive drugs of 2013 The price of Gilead Sciences’ breakthrough drug Sovaldi has drawn all of the attention this year. By pricing it at $85,000 for a 12-week course, Gilead Sciences ($GILD) has been pilloried by politicians, payers and providers. But as EvaluatePharma points out, at that price Sovaldi barely makes it into the top 20 most expensive drugs. number 19 to be exact, just above Novartis’ ($NVS) Gleevec and just below GlaxoSmithKline’s ($GSK) Mekinist. Sovaldi is pricey, but if you want to talk about really pricey, then look at the 10 …


Six Tech Trends That Will Shape the Pharmaceutical Industry in 2013 #pharma #careers

Posted On Aug 31 2017 by

#pharmaceutical industry overview 2013 # Six Tech Trends That Will Shape the Pharmaceutical Industry in 2013 Life sciences companies face unprecedented challenges as revenues come under pressure as a consequence of pricing pressures caused by healthcare reforms and austerity measures, increased competition, and challenges in bringing new drugs and other products to market. They are responding by focusing on growth opportunities in emerging markets, pursuing breakthrough innovation through collaboration with industry and academic partners, challenging and revolutionizing the traditional sales, marketing and research and development (R D) operating models and focusing on operational efficiency. Shifts in the behavior of patients …